PINNED
PINNED
Streamlining Biomanufacturing of Personalised Cancer Immunotherapies with Synthetic DNA
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
List view / Grid view
Articles
Beyond ‘simple’ biology – turning organoids, spheroids, and 3D tissue models into physiologically relevant high-content assays for drug discovery
Drug discovery is still hampered by the routine use of cell-based models that often fail to recapitulate the truly relevant biological complexity of the corresponding disease. Just moving from two- (2D) towards three-dimensional (3D) cell culture model systems like spheroids and organoids is not enough to generate truly representative and…
New frontiers in G protein-coupled receptor drug discovery
G protein-coupled receptors (GPCRs) are seven transmembrane spanning proteins that mediate the physiological responses to a broad array of stimuli, including photons, biogenic amines, peptides and large proteins. They represent the target of approximately one-third of all approved drugs,1 yet paradoxically remain a relatively under-exploited protein class.
Proteomics: cracking the molecular mystery of diseases and therapeutics
In the wake of the human genome project, molecular biology and genetic technologies are tremendously integrating into biomedical research. Currently, PCR, qPCR, and sequencing are key tools in the clinical laboratory for the detection and characterisation of microorganisms and genetic disorders.
Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
Omics-informed drug target discovery in combating emerging infectious diseases
The catastrophic consequences of ever-increasing rates of death from infectious diseases demands new experimental strategies for drug target selection and drug design. Over the last decade, the pharmaceutical industry has been wounded by several issues including failure of drug-development programmes, burgeoning cost of drug development, increasing regulatory control, lack of…
Webinar highlights: Harmonising drug-target binding data analytics on a single platform
Harmonising drug-target binding data analytics looks at building a single, integrated software platform for a future pharma research and development digital ecosystem. This webinar, sponsored by PerkinElmer, outlined the fundamentals of a design process where an experimental analytics data workflow was integrated into a more seamlessly interactive digital platform.
Webinar highlights: Recent advances in diagnostics and treatments – from small molecules to cellular therapies
The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.
Expert view: Three-dimensional cell cultures as predictive tools in early drug discovery
Three-dimensional cell cultures (spheroids, organoids) are becoming widely used as a new predictive tool in early drug discovery. The use of 3D cell cultures is believed to provide a more physiologically relevant response than monolayer (2D) cell cultures because they closely mimic the extracellular matrix and cell-cell interactions that occur…
Expert view: Challenges in drug discovery screening
The basic premise of drug discovery screening necessitates that the biological assays upon which it depends can be performed in a reproducible manner. In addition, the techniques employed must generate results that are biologically relevant and actionable.
Webinar highlights: Cell-based and biochemical high-throughput screening in 1536-well plates
The Small Molecule Screening Facility (SMSF) at the University of Wisconsin Madison is a comprehensive high-throughput screening (HTS) centre where researchers have investigated antibiotic-resistant bacterial infections and screening for protein-protein interactions using HTS methods.
Expert view: High-throughput screening – make an impact by removing barriers
For drug discovery and biomarker research, screening campaigns are employed to identify potential new treatments for diseases and to answer questions that remain unknown in the scientific community.
PAINS management: an open source model to eliminate nuisance compounds
High-throughput screening (HTS) technologies have enabled the routine testing of millions of compounds towards the identification of novel ‘hit’ molecules for therapeutic targets. Oftentimes in this drug discovery process, however, compounds that show promising activity in primary screens show no activity during subsequent hit qualification or progression efforts.
Application Notes supplement 2018
Researchers are always looking more effective and efficient ways of making their work more successful. In this supplement, some of our commercial partners share their data, detailing the application of their technology.
Webinar preview: Compliance with data integrity and computerised system validations
Data integrity and computerised system validations (CSV) have become an area of increased scrutiny for regulatory agencies over the last several years. Understanding how the agencies view data integrity is critical for laboratories to maintain complete compliance.
Self-delivering RNAi: paving the way for a new class of cancer immunotherapies
Earlier this year, the National Cancer Institute published its annual report to the nation on the status of cancer stating that there will be nearly 1.8 million new cases of cancer in 2018.1 New therapies have developed over time to improve cancer patient outcomes, including antibody immunotherapies targeting immune checkpoints,…
